82) inhibit the release of certain cytokines (tumor necrosis factor-α, interleukin-1β, |
83) Anti-tumor necrosis factor (anti-TNF) biologics |
84) Tumor necrosis factor-α (TNF-α), interle |
85) pond to methotrexate, treatment with anti-tumor necrosis factor (TNF)-α is an optio |
86) ing biochemical parameters were measured: tumor necrosis factor (TNF), interleukin-1 |
87) nstillation caused dose-trend increase in tumor necrosis factor alpha (TNF-α), inte |
88) ecretion of the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα) from h |
89) lial fibrillary acidic protein (GFAP) and tumor necrosis factor alpha (TNFα) levels |
90) e 34.55 ± 16.30 years) refractory to tumor necrosis factor blockers and standar |
91) Management of tumor necrosis factor receptor-associated |
92) e (NO), lung interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), hydr |
93) uding vascular endothelial growth factor, tumor necrosis factor-alpha (TNF-α), lept |
94) T induced by exposure of MCF-10A cells to tumor necrosis factor-α (TNF-α) and tran |
95) ogel was designed and employed to deliver tumor necrosis factor-α (TNF-α) locally |
96) dimethylarginine (ADMA) on the levels of tumor necrosis factor-α (TNF-α), interle |
97) ed generation of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). |
98) (HUVECs) together with the stimulation of tumor necrosis factor-α (TNF-α). |
99) inflammatory response molecules, such as tumor necrosis factor-α and intercellular |
100) ivity of Siglec-9, while the reduction in tumor necrosis factor-α was not affected. |
101) lular arrangement punctuated by sheets of tumor necrosis. |
102) individual "stress-history" of the given tumor. |
103) hell incision and completely resected the tumor. |
104) most common type of primary intracranial tumor. |
105) new possibility in the treatment of brain tumor. |
106) ed the concomitant existence of papillary tumor. |
107) vant treatment of a rectal adenocarcinoma tumor. |
108) benign, locally aggressive nasopharyngeal tumor. |
109) was interpreted as small blue round cell tumor. |
110) cinoma of the breast is an extremely rare tumor. |
111) ancers regardless of the histology of the tumor. |
112) t with growth hormone secreting pituitary tumor. |
113) findings after surgical resection of the tumor. |
114) re is no perfect single biomarker of this tumor. |
|